id: acamprosate_adherence_to_alcohol_abstinence_outcomes
name: Acamprosate Medication Adherence â†’ Alcohol Abstinence and Reduced Consumption
from_node:
  node_id: acamprosate_adherence
  node_name: Acamprosate Medication Adherence
to_node:
  node_id: alcohol_abstinence_outcomes
  node_name: Alcohol Abstinence and Reduced Consumption
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Regular acamprosate consumption maintains therapeutic drug levels that
  modulate glutamate and GABA neurotransmitter systems'
- 'Step 2: Neurochemical stabilization reduces physiological craving and withdrawal
  symptoms associated with alcohol dependence'
- 'Step 3: Reduced craving and withdrawal symptoms lower the biological drive to consume
  alcohol'
- 'Step 4: Sustained medication adherence supports maintenance of abstinence and reduced
  alcohol consumption over time'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'K. Donoghue et al. 2023. "Adjunctive Medication Management and
    Contingency Management to enhance adherence to acamprosate for alcohol dependence:
    the ADAM trial RCT.." *Health Technology Assessment*. https://doi.org/10.3310/DQKL6124'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.650861'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: baseline_abstinence_status
  direction: strengthens
  strength: moderate
  description: Trial included only participants who were abstinent from alcohol at
    baseline assessment, which may enhance medication effectiveness
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/acamprosate_adherence_to_alcohol_abstinence_outcomes.yaml
_category: healthcare_access
